At Aster Hospital Mankhool, we have achieved a monumental milestone: successfully performing over 10,000 catheterisation laboratory procedures since the inception of our Cath Lab in 2018.
This figure represents the total number…
Medical Oncology
A cancer diagnosis can have a significant impact on a person’s health and daily life. Cancer treatment therefore needs to address the disease while also considering its effects on the rest of the body.
Advances in medical oncology have led to more targeted systemic therapies that aim to control cancer while reducing unnecessary effects on healthy tissues and supporting the patient’s overall quality of life.
At Aster Hospitals, our medical oncology department provides advanced medical oncology treatment in Dubai. We use evidence-based systemic therapies designed to target cancer cells accurately while reducing damage to healthy tissue, helping patients complete their treatment regimens.
Medical oncology is the pharmacological frontline of cancer care. Medical oncology extends beyond prescribing medication to encompass comprehensive treatment planning, monitoring, and supportive care. It is the strategic use of systemic treatment agents to treat malignancies that have spread beyond a single, operable location, such as:
The objective is always to achieve remission or control growth, but doing so demands a deep understanding of how these drugs interact with both the tumour's genetic mutations and the patient's normal physiology.
Patients looking for cancer treatment in Dubai require medical oncology services when their condition demands a systemic rather than a purely local approach. This includes malignancies that have metastasised or locally advanced tumours that need to be shrunk before surgery can even be considered.
Whether dealing with an aggressive breast carcinoma, lung cancer, or a gastrointestinal tract malignancy, a medical oncologist in Dubai becomes essential when the disease is not confined to one spot. When localised treatments aren't enough, systemic therapy is the definitive step to regain control.
The treatment pathways depend on the cancer's origin, stage, and molecular markers. However, the clinical workflow follows a structured sequence mentioned below :
Before starting any medication, our experts carry out comprehensive imaging, biopsies, and genetic testing. Identifying the tumour's specific genetic mutations is essential for determining the appropriate pharmacological approach.
A tumour board reviews the pathology to determine the exact combination and dosage required, whether that involves traditional cytotoxic chemotherapy, immunotherapy, or targeted agents.
Depending on the regimen, patients receive medications intravenously in specialised infusion suites or orally. Delivery is carefully timed in cycles to maximise cancer cell death while allowing healthy cells time to recover.
Concurrent medication is a vital part of this process. We administer antiemetics, growth factors, and pain relief alongside the primary treatment to manage side effects.
Following each treatment cycle, we reassess the patient using imaging and tumour markers. If the cancer responds, we continue the current protocol. If not, we switch to an alternative line of therapy.
Recovery in medical oncology appears vastly different from surgery because there are no surgical wounds to heal, and the internal toll of systemic therapy requires significant endurance. Medical oncology treatment typically unfolds over several months, with patients visiting the hospital for scheduled infusion cycles.
Acute side effects, such as fatigue, nausea, or low blood counts, often peak in the days immediately after a session and subside before the next one. While many patients continue their daily routines, they still need to adjust work and rest. Full systemic recovery, particularly restoring bone marrow density and hormonal balance, can take several months after the final cycle.
Choosing an experienced oncology care provider is an important part of cancer treatment. An accurate diagnosis and appropriate treatment plan are essential from the beginning, particularly when patients seek care at the best oncology hospital in Dubai.
At Aster Hospitals, medical oncologists, pathologists and supportive care teams work closely to coordinate each stage of treatment, from diagnosis and treatment planning to monitoring and follow-up.
Patients choosing Aster Hospitals for targeted therapy benefit from:
Additionally, patients can access our medical oncology hospital in Dubai at our Mankhool and Al Qusais facilities.
Our specialists are experts in the systemic management of cancer. Recognised among the best oncologists in Dubai, they have extensive experience navigating complex cases and adjusting protocols for patients with compromised immune systems or rare tumour genetics. Their treatment plans are never one-size-fits-all, because the way a tumour mutates and how a patient tolerates therapy are rarely the same twice.
No. While chemotherapy is a core component, medical oncology also encompasses immunotherapy, targeted therapy, and hormonal therapy. A medical oncologist determines which systemic treatment or combination is best suited to fight the specific cancer based on its molecular profile.
Not necessarily. Supportive care has improved substantially in recent years. While chemotherapy can still cause fatigue and nausea, we use preventative medications to reduce these effects. Furthermore, targeted therapies and immunotherapies tend to have different, and sometimes less severe, side-effect profiles compared to traditional chemotherapy.
It varies widely based on the cancer type and stage. A single infusion session might take an hour, but a full course of treatment often spans three to six months, sometimes longer if maintenance therapy is required to keep the cancer in remission.
Often, yes. Medical oncology frequently works in tandem with surgical oncology or radiation oncology. For instance, systemic therapy might be used to shrink a tumour before a surgeon removes it, or prescribed post-surgery to eliminate any residual microscopic cancer cells.
Last updated: 02-11-2026